MyBlueDotsMeiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy MyBlueDots2 weeks ago01 mins TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network. Go to Source Author: Post navigation Previous: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNext: Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
People who are autistic and transgender/gender diverse have poorer health and health care, study finds MyBlueDots6 hours ago 0
Digital therapeutics: Exploring the road to commercialization across international markets MyBlueDots11 hours ago 0